Laboratory compliance with the American society of clinical Oncology/College of American Pathologists guidelines for human epidermal growth factor receptor 2 testing a college of American Pathologists survey of 757 laboratories

Archives of Pathology and Laboratory Medicine

Volumn 134, Issue 5, 2010, Pages 728-734

  Nakhleh, Raouf E ^a   Grimm, Erin E ^b   Idowu, Michael O ^c   Souers, Rhona J ^d   Fitzgibbons, Patrick L ^e  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d Molecular Pathology Division   (United States)

^e ST JUDE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN;

ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HEALTH CARE QUALITY; HEALTH CARE SURVEY; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY; LABORATORY DIAGNOSIS; METABOLISM; ONCOLOGY; PATHOLOGY; PRACTICE GUIDELINE; QUESTIONNAIRE; REGRESSION ANALYSIS; STANDARD;

GUIDELINES AS TOPIC; HEALTH CARE SURVEYS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LABORATORIES; MEDICAL ONCOLOGY; PATHOLOGY, SURGICAL; QUALITY OF HEALTH CARE; QUESTIONNAIRES; RECEPTOR, ERBB-2; REGRESSION ANALYSIS; SPECIMEN HANDLING;

EID: 77952067396     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006;354(20):2103-2111.
2. Villman K, Sjostrom J, Heikkila R, et al. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer. Acta Oncol. 2006;45(5):590-596.
3. Konecney GE, Thomssen C, Lück HJ, et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst. 2004;96(15):1141-1151. (Pubitemid 39207050)
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792.
5. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719-726.
6. Wolf AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal grown factor receptor 2 testing in breast Cancer. Arch Pathol Lab Med. 2007;131(1):18-43.
7. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94(11):853-854.
8. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 2002;94(11):855-857.
9. Commission on Laboratory Accreditation. Standards ANP.22997, ANP.22998, ANP. 22999 of the anatomic checklist of the Laboratory Accreditation Program. Northfield, IL: College of American Pathologists. Adopted on: September 27, 2007.
10. Fitzgibbons PL, Murphy DA, Dorfman DM, Roche PC, Tubbs RR; for the Immunohistochemistry Committee, College of American Pathologists. Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey. Arch Pathol Lab Med. 2006;130(10):1440-1445.
11. Clinical Laboratory Improvement Amendments of 1988; final rule. Fed Reg. 1992;57:7001-7186. To be codified at 42 CFR 1405.
12. Black-Schaffer WS, Young RH, Harris NL. Subspecialization of surgical pathology at the Massachusetts General Hospital. Am J Clin Pathol. 1996;106(4)(suppl 1):S33-S42.
13. Gown AM. Current issues in ER and HER2 testing by IHC in breast Cancer. Mod Pathol. 2008;21(suppl 2):S8-S15.